Dyne Therapeutics, Inc. (DYN)

Market Cap	3.39B
Revenue (ttm)	n/a
Net Income (ttm)	-257.40M
Shares Out	97.88M
EPS (ttm)	-3.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	775,595
Open	35.25
Previous Close	35.49
Day's Range	34.19 - 35.43
52-Week Range	6.40 - 36.60
Beta	1.06
Analysts	Strong Buy
Price Target	40.22 (+16.08%)
Earnings Date	Aug 1, 2024

About DYN

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2020
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: DYN

Analyst Forecast

According to 9 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price forecast is $40.22, which is an increase of 16.08% from the latest price.

Price Target

$40.22

(16.08% upside)

Analyst Consensus: Strong Buy